VMRC-RCZ

The VMRC-RCZ cell line is a human renal cell carcinoma (RCC) line established from a patient with clear cell type kidney cancer. It was derived to investigate the biological and genetic underpinnings of renal carcinogenesis, particularly with regard to chromosomal abnormalities and tumor progression. Cytogenetic analysis of VMRC-RCZ has revealed deletion of the short arm of chromosome 9, specifically within the 9p21-22 region. This deletion implicates the loss of key tumor suppressor genes such as CDKN2A, which is commonly associated with various malignancies and plays a role in cell cycle regulation.

In broader cancer genome analyses, VMRC-RCZ has contributed to the mapping of homozygous deletions across multiple tumor types. These studies show that regions like 9p21 often exhibit structural instability in cancer cell lines, including VMRC-RCZ, suggesting that genomic deletions in this region may confer a selective growth advantage during tumor evolution. Additionally, VMRC-RCZ has been incorporated into high-resolution genomic profiling platforms for the systematic identification of cancer-related mutations and copy number alterations, making it a valuable model for studying RCC pathogenesis and for the exploration of potential therapeutic vulnerabilities in renal malignancies.